Renaissance Technologies LLC Has $11.93 Million Position in MiMedx Group, Inc $MDXG

Renaissance Technologies LLC grew its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 22.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,019,871 shares of the company’s stock after acquiring an additional 552,806 shares during the quarter. Renaissance Technologies LLC’s holdings in MiMedx Group were worth $11,928,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. SkyView Investment Advisors LLC boosted its stake in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares during the last quarter. Rafferty Asset Management LLC increased its stake in MiMedx Group by 4.6% in the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after purchasing an additional 3,064 shares in the last quarter. Aviva PLC raised its holdings in MiMedx Group by 4.7% in the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after purchasing an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Trading Down 3.3%

MDXG opened at $4.13 on Friday. The stock has a market capitalization of $601.99 million, a P/E ratio of 103.28 and a beta of 1.45. MiMedx Group, Inc has a 12 month low of $3.03 and a 12 month high of $7.99. The firm’s fifty day simple moving average is $3.92 and its 200 day simple moving average is $4.24. The company has a current ratio of 5.33, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The firm had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. As a group, research analysts anticipate that MiMedx Group, Inc will post -0.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Craig Hallum decreased their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, Citizens Jmp decreased their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.